344 Avelumab + binimetinib in metastatic pancreatic ductal adenocarcinoma (mPDAC): dose-escalation results from the phase 1b/2 JAVELIN PARP MEKi trial
oleh: Nathan Bahary, Sylvie Rottey, Wells Messersmith, Zhou Zhu, Jordi Rodon, Wael Harb, Daniel Weng Tan, Ignacio Garrido Laguna, J Thaddeus Beck, Shibing Deng, Karen Kowalski, Grainne O’Neill, Caimiao Wei, Nuzhat Pathan
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2021-11-01 |
Deskripsi
No description available for this item.